基于MRI的影像组学预测结直肠癌肝转移系统治疗的病理缓解:一项多中心研究
这项回顾性双中心研究纳入2018至2021年接受奥沙利铂/伊立替康为基础化疗后切除的结直肠癌肝转移患者162例,分析化疗后钆塞酸二钠增强MRI门静脉期和肝胆期的肿瘤及瘤周影像组学特征。结合临床变量与影像组学特征的模型在验证集预测病理缓解的准确度0.773、敏感度0.724、特异度0.812、ROC-AUC 0.860,优于纯临床模型(p<0.001)。
要点
- 131例影像学部分缓解患者中59例(45%)病理无肿瘤退缩(TRG4-5)。
- 联合临床与影像组学模型验证集ROC-AUC 0.860,优于纯临床模型(p<0.001)。
- 门静脉期肿瘤VOI与肝胆期瘤周VOI提取的特征贡献最大。
核心结论
- 化疗后钆塞酸二钠增强MRI门静脉期和肝胆期提取的影像组学特征联合临床变量,可增强对结直肠癌肝转移化疗病理缓解(TRG)的无创评估。
研究设计与样本
- 回顾性双中心研究,纳入2018至2021年接受奥沙利铂/伊立替康为基础术前化疗后切除的结直肠癌肝转移连续患者162例(中位年龄62.5岁,男性102例)。
诊断标准与关键数值
- 纳入末次再分期为疾病稳定或部分缓解且化疗后MRI距手术≤60天的患者,分析最大病灶(≥10 mm);在门静脉期和肝胆期手动勾画肿瘤VOI并自动生成5 mm瘤周组织环(Margin-VOI)后手动校正。
临床应用与阅片要点
- 模型包含临床变量及门静脉期与肝胆期肿瘤VOI/瘤周VOI影像组学特征,验证集准确度0.773、敏感度0.724、特异度0.812、ROC-AUC 0.860,联合模型优于纯临床模型(p<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Tumor response to preoperative chemotherapy is a key prognostic factor for colorectal liver metastases (CRLM), but an accurate non-invasive assessment remains an unmet need.
OBJECTIVE: To assess the contribution of radiomic analysis of preoperative, post-chemotherapy, gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI to the non-invasive prediction of the pathologic response to systemic therapy of CRLM.
METHODS: This retrospective bi-institutional study included all consecutive patients undergoing resection for CRLM (2018-2021) after preoperative oxaliplatin/irinotecan-based chemotherapy. We selected patients with stable disease or partial response at the last restaging, and with post-chemotherapy MRI performed ≤60 days before surgery. The largest CRLM (≥10 mm) was analyzed. Pathologic response was evaluated according to the TRG. The tumor (Tumor-VOI) was manually segmented on the portal venous phase (PVP) and hepatobiliary phase (HBP) sequences; a 5-mm ring of peritumoral tissue was automatically generated (Margin-VOI) and manually corrected. The predictive models underwent internal validation.
RESULTS: Overall, 162 patients (median age 62.5 years, 102 men) were evaluated. Of the 131 patients with a radiologic partial response, 59 (45 %) had no tumor regression at pathology (TRG4-5). The model including both clinical variables and radiomic features extracted from the Tumor-VOI/Margin-VOI of PVP and HBP achieved the best performances: at validation, Accuracy = 0.773, Sensitivity = 0.724, Specificity = 0.812, and ROC-AUC = 0.860. The combined clinical-radiomic model outperformed the pure clinical one (p < 0.001). The features extracted from the Tumor-VOI in PVP and Margin-VOI in HBP had the highest impact.
CONCLUSION: The addition of radiomic features extracted from the PVP and HBP of post-chemotherapy Gd-EOB-DTPA-enhanced MRI enhanced standard radiologic and clinical assessment of CRLM response to chemotherapy, providing a reliable non-invasive assessment of TRG.
引用
- Ammirabile A, Levi R, Boldrini L, et al. MRI-based radiomics predicts the pathologic response of colorectal liver metastases to systemic therapy: A multicenter study. Eur J Radiol. 2025. PMID: 40752452. doi:10.1016/j.ejrad.2025.112325
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。